This approach is particularly valuable when counseling individuals with variants in moderate-penetrance breast cancer genes like CHEK2, ATM, RAD51C, RAD51D, and BARD1, since the relative effect of risk factors is expected to be higher than in individuals with high-penetrance PVs. This evidence concerns the gene RAD51D and breast carcinoma.